
Benzinga Pro data, Ayala Pharmaceuticals (NASDAQ:AYLA) reported Q4 sales of $1.15 million. Earnings fell to a loss of $10.05 million, resulting in a 2.58% decrease from last quarter. Ayala Pharmaceuticals collected $625.00 thousand in revenue during Q3, but reported earnings showed a $9.80 million loss.